Michael Rosenblum is Associate Professor of Dermatology at in the Department of Dermatology at the University of California, San Francisco (UCSF) and is one of the world's leading skin immunologists. Michael’s research focuses on understanding the fundamental mechanisms of how immune responses are regulated in peripheral tissues, and how this knowledge can be exploited to treat human disease. He recently helped to generate and validate a novel therapeutic molecule that selectively activates human regulatory T cells, taken into clinical trials in patients with autoimmune diseases.
Michael is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists, the NIH Director’s New Innovator Award, the Dermatology Foundation’s Charles & Daneen Stiefel Scholar Award in Autoimmune & Connective Tissue Diseases, as well as multiple NIH R01 & R21 awards. Most recently, Michael was named the William Montagna Lecturer by the Society for Investigative Dermatology. He has authored 80 basic science research papers. Michael was a co-founder of TRex Bio and the scientific co-founder of Delinia Bio, which was sold to Celgene in 2017.
Michael received his medical degree and PhD in Immunology from the Medical College of Wisconsin. He completed his dermatology residency training at UCSF in the prestigious Physician-Scientist Training Pathway before joining the UCSF faculty in 2012.
- Skin-resident T cells drive dermal dendritic cell migration in response to tissue self-antigen. Journal of Immunology (2018), 200(9), 3100-3108.
- Regulatory T cells in skin. Immunology (2017), 152(3), 372-381.
- Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell (2017), 169(6), 1119-1129.
- The distribution of cutaneous metastases correlates with local immunologic milieu. Journal of the American Academy of Dermatology (2016), 74(3), 470-476.
- Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. The Journal of Clinical Investigation (2016), 126(9), 3447-3452.